SUMOylation of Mouse p53b by SUMO-1 Promotes Its Pro-Apoptotic Function in Ovarian Granulosa Cells

Xiao-Ming Liu, Fei-Fei Yang, Yi-Feng Yuan, Rui Zhai, Li-Jun Huo*

Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction, Education Ministry of China, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, People’s Republic of China

Abstract

Follicular atresia is a process of spontaneous degradation of follicles, hindering growth and development in the mammalian ovary. Previous studies showed that follicular atresia was caused by apoptosis of granulosa cells, for which a number of apoptosis-related genes have already been identified. The roles of p53 in apoptosis of mouse granulosa cells and its post-translational modification are still unclear. The main objective of this study was to explore the roles of p53 in mouse granulosa cells. We found that mouse p53b, but not p53a, could be SUMOylated by SUMO-1 at lysine 375, which was essential for the protein stability of p53b in a dose-dependent manner. Immunofluorescent staining showed that wild p53b was located in the nucleus of granulosa cells, while its mutation of SUMOylation site (K375R) was localized in both nucleus and cytoplasm, implying that SUMOylation was necessary for the nuclear localization of p53b in granulosa cells. Overexpression of wild-type p53b, but not the mutation of SUMOylation site (K375R), significantly induced the expression of apoptosis-related gene, Bax, and increased the level of apoptosis in granulosa cells. This suggested that SUMO-1 modification of p53b was essential for inducing apoptosis in granulosa cells. Our results provide strong evidences that modification of p53b by SUMO-1 at lysine 375 was necessary for its activity to induce apoptosis in mouse granulosa cells, and it was involved in the regulation of p53b protein stability and nuclear localization. This implies that modification of p53b by SUMO-1 might regulate follicular atresia by inducing the apoptosis of ovarian granulosa cells in mice.

Introduction

During the process of follicular atresia, follicles spontaneously degrade in the mammalian ovary, hindering growth and development. More than 99% of follicles disappear, primarily due to apoptosis of granulosa cells [1–6]. Although atresia can occur at any time during follicular development, the majority of follicles become atretic during the early antral stage of development [7]. The transition from preantral to antral follicles occurs after the granulosa cells are exposed to gonadotropin. The gonadotropin initiates differentiation of the granulosa cells making them susceptible to apoptosis.

Apoptosis in granulosa cells is characterized by nucleosome DNA fragmentation, cell shrinkage, membrane blistering, and the formation of apoptotic bodies [8]. Many apoptosis-related factors have been implicated in follicular atresia, including death ligands and receptors, intracellular pro- and anti-apoptotic molecules, cytokines, growth factors, and a number of apoptosis-related genes, including the p53 gene [9–11].

The p53 protein is an antiproliferative transcription factor that increases the rate of transcription of various genes involved in mitosis and apoptosis [9,12–15]. It plays a critical role in cell cycle regulation (G1/S transition), DNA repair, and induction of apoptosis [14,16–18]. In granulosa cells, p53 content is correlated with contents of Fas and FasL, death ligands that are involved in the induction of apoptosis and are regulated by gonadotropins [19]. When gonadotropin induced, p53 becomes markedly elevated, suggesting that induction of atresia is p53-dependent [20]. Furthermore, overexpression of p53 resulted in increased Fas content and apoptosis [16]. However, mouse p53 gene contains only a promoter, which differs from the selective promoter of the human p53 gene; the alternatively spliced RNA species of tumor-suppressor gene p53 (which contains an additional 96 bases derived from intron 10) is present at approximately 25 to 30% the level of regularly spliced p53 RNA in both normal epidermal cells, carcinoma cells, and mouse liver and testis cells [21]. Precisely because of this alternative splicing, there are two types of p53 protein: p53a encodes 390 amino acids and p53b encodes 381 amino acids. The main difference between p53a and p53b is the C-terminal sequence. However, the biological properties of different types of the p53 protein in mice have not yet been determined.

The half-life of the p53 protein in normal cells is increased when the cells are exposed to various kinds of external stimuli. These stimuli influence the post-translational events and the stability of the protein, including acetylation, methylation, phosphorylation, ubiquitination, neddylation, and SUMOylation [22–24]. The small ubiquitin-related modifier-1 (SUMO-1) is an ubiquitin-related protein that was discovered in the yeast Saccharomyces cerevisiae in 1995 [25,26]; SUMO-1 is involved in many cellular
processes, including cell proliferation, differentiation, and apoptosis [25,27]. Studies have reported that human p53 can be modified by SUMO-1 and the SUMOylation site is lysine306 [28–30]. Conjugation of SUMO-1 to wild-type p53 results in an increased transactivation ability of p53 [28,30]. However, SUMOylation has no effect on mutant p53 transcriptional activity [29,31]. In addition to comparing wild-type and SUMOylation-deficient p53 for transactivation, studies analyzed potential differences in localization and growth inhibition or apoptosis. Mutating the p53 SUMO-acceptor site lysine306 to arginine had no obvious effect on p53 localization [29], but one study generated p53-SUMO-1 fusion protein as a model for the effect of SUMO modification on the localization and function of p53, showing that p53-SUMO-1 fusion protein significantly redistributed from the nucleus to the cytoplasm when the SUMOylation site lysine306 was destroyed [32]. Studies showed the SUMOylation of p53 to the cytoplasm when the SUMOylation site lysine386 in the p53 SUMO-acceptor site lysine386 to arginine had no obvious addition to comparing wild-type and SUMOylation-deficient p53. No obvious effect on mutant p53 transcriptional activity [29,31]. In addition, SUMOylation enhanced the apoptosis in Saos-2 cells [33]. In addition, SUMOylation of p53 has been shown to affect its transcriptional activity [29,31].

Materials and Methods

Objective is to explore the roles of p53 in mouse granulosa cells and SUMOylation of p53 in regulating follicular atresia and granulosa cells apoptosis, and its regulatory mechanism is also unclear. Furthermore, there are two types of p53 protein (p53a and p53b) in mice, and the roles of these p53 forms in mouse granulosa cells and whether they can be SUMOylated have not been reported. In this study, the main objective is to explore the roles of p53 in mouse granulosa cells and the effects of SUMOylation.

Experimental Animals

We obtained immature 21 to 23 d-old Kunming White female mice from the Centre of Laboratory Animals of Hubei Province (Wuhan, PR China). All animal treatment procedures were approved by the Ethical Committee of the Hubei Research Center of Experimental Animals (Approval ID: SCXK (Hubei) 2008-0005). Mice were housed under controlled temperature (24°C) and lighting (12 h light/12 h darkness) with food and water ad libitum. Follicle development was primed by injection of each mouse with 10 IU pregnant mare serum gonadotropin (PMSG; SanSheng, Ningbo), and mice were killed by cervical dislocation 44–48 h later.

Plasmid Construction

A 1310-bp mouse p53a and a 1213-bp mouse p53b cDNA sequence were amplified using polymerase chain reaction (PCR) from mouse ovary cDNA using the following primers: p53a- Forward 5'-CCGGATCCGGCAGGTTGTCAGGCTTCT-3'; p53a- Reverse 5'-CGGAGATTCGAGGAGGATGATTG-3'; p53b- Forward 5'-CCGGATCCGGCAGGTTGTCAGGCTTCT-3'; and p53b- Reverse 5'-CGGAGATTCGAGGAGGATGATTG-3'. Both in- cluded BamHI and EcoRI restriction sites. We subcloned into pCMV-N-HA to generate a HA-tagged p53a and p53b cDNA.

In vitro Culture of Granulosa Cells and DNA Transfection

Granulosa cells from pre-ovulatory follicles (pre-GCs) were obtained from ovaries of 21 to 23 d-old Kunming White female mice injected with 10 IU PMSG (SanSheng, Ningbo) 44–48 h. Granulosa cells were cultured in 6-well culture plates in Dulbecco’s Modified Eagle’s Medium/Nutrient F-12 (DMEM/F12; Gibco) medium with 10% fetal bovine serum (FBS; Invitrogen), 60 mg/mL penicillin, and 50 mg/mL streptomycin. All cultures were maintained in DMEM/F12 medium at 37°C in a humidified atmosphere of 5% CO2. After being cultured 24 h, granulosa cells were washed by phosphate-buffered saline (PBS), and cultured for 24 h in fresh serum-free DMEM/F12 medium before DNA transfections.

For DNA transfection or co-transfection, granulosa cells were plated and then transfected with 4 μg of the desired plasmids for 24 h with Lipofectamine LTX (Invitrogen) according to manufacturer’s instructions. Desired plasmids and LTX were diluted in Opti-MEM (Gibco) medium and incubated for 5 min. This solution was then mixed with granulosa cells at a proportion of 1:1.5 for 30 min; 24 h after transfection, granulosa cells were collected for protein extraction or apoptosis analysis.

To study the effect of SUMO-1 mediated modification of p53b on its protein level in granulosa cells, different dosages of pCMV-Flag-sumo-1 plasmids (2 μg, 3 μg, 4 μg, and 6 μg) were co-transfected with a fixed proportion of pCMV-HA-p53b or pCMV-HA-p53bK375R (2 μg) plasmids into granulosa cell.

Protein Extraction, Immunoprecipitation and Western Blot Analysis

Subconfluent cells seeded on 6-well culture plates were transfected with the expression vectors indicated. At 24 h after transfection, cells were washed twice with ice-cold PBS and harvested in 80 μL of ice-cold RIPA buffer (Santa Cruz) containing 10 μM phenylmethylsulfonyl fluoride (PMSF; Ding-Guo, Beijing) and 10 mg/mL protease inhibitors cocktail (Santa Cruz). Protein lysis was performed on ice for 20 min. Then, the lysates were centrifuged at 12000 rpm for 5 min, and the supernatant was collected and stored at −80°C.

The concentration of total protein was determined by bicinchoninic acid (BCA) assay (Pierce, Rockford, USA), and 20 μg of total protein was subjected to gel electrophoresis. The cell lysates mixed with 2× SDS gel-loading buffer were loaded on 4% stacking gel and 10% separating gel, and were then transferred to 0.2 μm polyvinylidene fluoride (PVDF) membrane (Milli-pore, Bedford, MA). After blocking in TBST [10 mM Tris (pH 7.5), 150 mM NaCl and 0.05% Tween 20] containing 5% skimmed milk (Sigma-Aldrich), membranes were incubated with the corresponding primary antibody diluted in blocking buffer overnight at 4°C. Polyclonal rabbit anti-p53 IgG (1:500 dilution; Boster, Wuhan), monoclonal mouse anti-β-actin IgG (1:500 dilution; Santa Cruz), and monoclonal mouse anti-HA IgG (1:750 dilution; CWBIO, Beijing) were used as the primary antibody, respectively. After incubation with the primary antibody, the membrane was washed three times in TBST, and incubated with HRP-conjugated secondary antibodies diluted in TBST for 1 h at room temperature, then washed three times in TBST. Chemiluminescent detection was performed using ECL Western blot detection reagents (Amersham Biosciences, Piscataway, NJ). To analyze the SUMO-1 modifi-
cation of p53 protein, membranes were probed with the HA antibody or p53 antibody, respectively, while the membrane was probed with β-actin antibody for normalization. The band intensities were measured with Gel-Pro analyzer 4.0 (Media Cybernetics, USA).

Immunoprecipitation (IP) was conducted to detect if p53 could be modified by SUMO-1 in granulosa cells in vivo. Briefly, after transfection with pCMV-Flag-sumo-1 plasmid or pCMV-Flag plasmid (as a negative control), granulosa cells (10^5–10^6) were harvested in 1 mL lysis buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) containing 10 µM PMSE (DingGuo, Beijing) and 10 mg/mL protease inhibitors cocktail (Santa Cruz). The extract was centrifuged at 12,000 g for 15 min at 4°C, and the supernatant were incubated with ANTI-FLAG M2 Affinity beads (Sigma-Aldrich) overnight at 4°C with continual shaking. After elution, the beads were centrifuged at 8,000 g for 30 s and the supernatant was collected. For Western blot, the supernatant was mixed with equal volume of 2× SDS loading buffer and heated for 5 min at 100°C before being loaded on a SDS-PAGE gel. Polyclonal rabbit anti-p53 IgG was used as the primary antibody.

In order to confirm which type of p53 (p53a or p53b) could be modified by SUMO-1, granulosa cells were co-transfected with pCMV-Flag-sumo-1 plasmid and pCMV-HA-p53a plasmid or pCMV-HA-p53b plasmid. After transfection, Flag-tagged SUMO-1 were pulled down by Flag antibody and then HA antibody were used to detect the expression of p53a or p53b by Western blot.

Immunofluorescence Cytochemistry

In order to detect the subcellular localization pattern of p53b and p53bK375R, pre-GCs were plated on coverslips and transfected with pCMV-N-HA-p53b or pCMV-N-HA-p53bK375R vector respectively. After 24 h transfection, cells were washed twice with PBS and were fixed in 4% paraformaldehyde (Santa-Aldrich) overnight at 4°C with gentle shaking for 30 min. After elution, the beads were centrifuged at 8,000 g for 30 s and the supernatant was collected. For Western blot, the supernatant was mixed with equal volume of 2× SDS loading buffer and heated for 5 min at 100°C before being loaded on a SDS-PAGE gel. Polyclonal rabbit anti-p53 IgG was used as the primary antibody.

In order to confirm which type of p53 (p53a or p53b) could be modified by SUMO-1, granulosa cells were co-transfected with pCMV-Flag-sumo-1 plasmid and pCMV-HA-p53a plasmid or pCMV-HA-p53b plasmid. After transfection, Flag-tagged SUMO-1 were pulled down by Flag antibody and then HA antibody were used to detect the expression of p53a or p53b by Western blot.

Cell Apoptosis Assay

Pre-GCs were transfected with pCMV-N-HA-p53b, pCMV-N-HA-p53bK375R, or negative control pCMV-N-HA for 24 h. Cells were washed twice in PBS, then trypsinized and collected for apoptosis assay. Apoptosis was performed by using the AnnexinV kit (AntGene, Wuhan) according to manufacturer’s instructions. Cells were incubated in AnnexinV–FITC and PI solution at room temperature in the dark for 15 min, then 300 µL of 1× binding buffer was added to each sample. Flow cytometric analysis was conducted using a BD FACScalibur (Becton, Dickinson and Company, USA; Ex, 480 nm and Em, 550 nm).

Real-time RT-PCR Analysis

To determine genes regulated by SUMOylation of p53b, at 24 h after transfection, total RNA was prepared using the RNAiso Plus (TaKaRa, Dalian), and in vitro transcription was carried out using PrimeScript RT reagent Kit With gDNA Eraser (TaKaRa, Dalian). Real-time PCR was then conducted to quantify the steady-state mRNA levels of the tested genes using SooFast™ EvaGreen® Supermix (BioRad, USA) on the Bio-Rad CFX96 Real-time PCR System. The threshold cycle (Ct) was used to determine the relative expression level of each gene by normalizing to the Ct of β-actin mRNA. The method of 2^-ΔΔCt was used to calculate the relative fold change of each gene. To ensure that only target-gene sequence-specific, non-genomic products were amplified by real-time PCR, careful design and validation of each primer pair, as well as cautious manipulation of RNA, were undertaken to quantity the steady-state mRNA levels of Bax and housekeeping gene β-actin (internal control). The primers used were Bax- forward: 5-CCAGGATGGTCGTCACCAA-3; Bax-reverse: 5-CAGAATACAGGGGCTACAC-3; β-actin- forward: 5-CCCATCTACGGGCTAT-3; and β-actin- reverse: 5-TGTACCGACGATTCC-3. Calculation of the relative fold change of Bax was done using the method of 2^-ΔΔCt. In each experiment, levels of Bax mRNA were presented as relative changes to a specific group (control), in which its expression level was set at 1.

Data Analysis and Statistics

All experiments were performed independently at least three times, and data are presented as mean ± SD. Differences between groups were analyzed by one-way ANOVA followed by Tukey’s Honestly Significant Difference (HSD) test using SPSS (Version 17.0; SPSS, Chicago, IL, USA). P<0.05 was considered significantly different, and P<0.01 was extremely significantly different.

Results

SUMOylation Increased the Expression Level of Mouse p53b Protein

At 24 h after transfection, total proteins were extracted from the cells and analyzed by Western blot using the HA-specific antibody or p53-specific antibody. After transfection with p53a or p53b plasmid, the expression of HA-p53 fusion protein or increased level of p53 protein could be observed (Fig. 1, lanes 3 and 4). Interestingly, after transfection with HA-sumo-1 or HA-ubc9 plasmid, a shifting-up band detected by using anti-HA antibody was also visible (Fig. 1, lanes 5 and 6), which was consistent with a form of protein that was covalently modified by HA-SUMO-1 or HA-UBC9. More importantly, the expression of p53 protein was significantly increased by transfection with sumo-1 or ubc9 plasmid (Fig. 1, lanes 5 and 6). Thus we predicted that the shifting band detected by HA antibody represented HA-SUMO-1-p53 fusion protein.
SUMO-1 Conjugation to p53b in vivo Requires Lysine 375

Based on the results above, we speculated that the mouse p53 protein could also be modified by SUMO-1. Immunoprecipitation (IP) study was designed to confirm whether mouse p53 could be SUMO-1 modified or not in granulosa cells. Pre-GCs were transfected with pCMV-Flag-sumo-1 plasmid or pCMV-Flag plasmid (as a negative control) for 24 h. Flag-tagged protein were pulled down by anti-Flag affinity beads and then analyzed by Western blot using anti-p53 antibody. A visible band of p53 was observed in the sample of pCMV-Flag-sumo-1 transfected granulosa cells, but not in the control sample (Fig. 2A). This study clearly showed that mouse p53 protein could be SUMO-1 modified in granulosa cells in vivo. However, there are two types of p53 in mouse, and which type of p53 that could be modified was unknown. Previous studies showed lys386 of human p53 was required for SUMO-1 modification in Saos-2 cells [29,35,36]. To identify which type of mouse p53 could be modified by SUMO-1 in mouse, we aligned the protein sequence of mouse p55a and p53b to human p53 around the SUMOylation site at lys386 (Fig. 2B). The lysine 375 of 374IKEE377 in mouse p53b was aligned to the lysine within the consensus SUMOylation site of human p53, 385FKTE388 (Fig. 2B). The region 374IKEE377 of mouse p53b was also confirmed as a high probability SUMOylation site, with a score of 2.943 predicted by SUMOsp2.0.4 software. However, there are no conserved amino acids in mouse p53a with mouse p53b at lys375 or human p53 at lys386, and there are no SUMOylated sites in mouse p53a predicted by SUMOsp2.0.4 software. In order to further confirm if only p53b, but not p53a, could be SUMO-1 modified in granulosa cells, pre-GCs were co-transfected with Flag-tagged sumo-1 plasmid and HA-tagged p53a or p53b plasmid. After transfection, the Flag-tagged fusion protein were pulled down by Flag antibody and then detected by Western blot using HA antibody. The results showed that only p53b, but not p53a, could be co-immunoprecipitated by Flag-tagged sumo-1 (Fig. 2C).

Although Lys375 of p53b were predicted by SUMOsp2.0.4 software as a putative SUMOylation site, it is still unknown whether this Lys375 is necessary for p53b's modification by SUMO-1. Therefore, we mutated lysine 375 of mouse p53b to arginine and generated a mutant, HA-tagged p53b (K375R) expression plasmid. Wild-type p53b plasmid or mutant p53b plasmid, with sumo-1 plasmid, were co-transfected into mouse Pre-GCs were co-transfected with Flag-tagged sumo-1 plasmid and HA-tagged p53a or HA-tagged p53b plasmid. Flag-tagged proteins were pulled down by anti-Flag affinity beads and then analyzed by Western blot using anti-HA antibody. A band of p53 (p53b) was detected in the sample of Flag-sumo-1 plasmid and HA-p53b plasmid co-transfected granulosa cells, but not in the negative control sample (Fig. 2A). This study clearly showed that mouse p53b protein could be SUMO-1 modified in granulosa cells in vivo. However, there are two types of p53 in mouse, and which type of p53 that could be modified was unknown. Previous studies showed lys386 of human p53 was required for SUMO-1 modification in Saos-2 cells [29,35,36]. To identify which type of mouse p53 could be modified by SUMO-1 in mouse, we aligned the protein sequence of mouse p55a and p53b to human p53 around the SUMOylation site at lys386 (Fig. 2B). The lysine 375 of 374IKEE377 in mouse p53b was aligned to the lysine within the consensus SUMOylation site of human p53, 385FKTE388 (Fig. 2B). The region 374IKEE377 of mouse p53b was also confirmed as a high probability SUMOylation site, with a score of 2.943 predicted by SUMOsp2.0.4 software. However, there are no conserved amino acids in mouse p53a with mouse p53b at lys375 or human p53 at lys386, and there are no SUMOylated sites in mouse p53a predicted by SUMOsp2.0.4 software. In order to further confirm if only p53b, but not p53a, could be SUMO-1 modified in granulosa cells, pre-GCs were co-transfected with Flag-tagged sumo-1 plasmid and HA-tagged p53a or p53b plasmid. After transfection, the Flag-tagged fusion protein were pulled down by Flag antibody and then detected by Western blot using HA antibody. The results showed that only p53b, but not p53a, could be co-immunoprecipitated by Flag-tagged sumo-1 (Fig. 2C).

Although Lys375 of p53b were predicted by SUMOsp2.0.4 software as a putative SUMOylation site, it is still unknown whether this Lys375 is necessary for p53b’s modification by SUMO-1. Therefore, we mutated lysine 375 of mouse p53b to arginine and generated a mutant, HA-tagged p53b (K375R) expression plasmid. Wild-type p53b plasmid or mutant p53b plasmid, with sumo-1 plasmid, were co-transfected into mouse Pre-GCs were co-transfected with Flag-tagged sumo-1 plasmid and HA-tagged p53a or HA-tagged p53b plasmid. Flag-tagged proteins were pulled down by anti-Flag affinity beads and then analyzed by Western blot using anti-HA antibody. A band of p53 (p53b) was detected in the sample of Flag-sumo-1 plasmid and HA-p53b plasmid co-transfected granulosa cells, but not in the negative control sample (Fig. 2A). This study clearly showed that mouse p53b protein could be SUMO-1 modified in granulosa cells in vivo. However, there are two types of p53 in mouse, and which type of p53 that could be modified was unknown. Previous studies showed lys386 of human p53 was required for SUMO-1 modification in Saos-2 cells [29,35,36]. To identify which type of mouse p53 could be modified by SUMO-1 in mouse, we aligned the protein sequence of mouse p55a and p53b to human p53 around the SUMOylation site at lys386 (Fig. 2B). The lysine 375 of 374IKEE377 in mouse p53b was aligned to the lysine within the consensus SUMOylation site of human p53, 385FKTE388 (Fig. 2B). The region 374IKEE377 of mouse p53b was also confirmed as a high probability SUMOylation site, with a score of 2.943 predicted by SUMOsp2.0.4 software. However, there are no conserved amino acids in mouse p53a with mouse p53b at lys375 or human p53 at lys386, and there are no SUMOylated sites in mouse p53a predicted by SUMOsp2.0.4 software. In order to further confirm if only p53b, but not p53a, could be SUMO-1 modified in granulosa cells, pre-GCs were co-transfected with Flag-tagged sumo-1 plasmid and HA-tagged p53a or p53b plasmid. After transfection, the Flag-tagged fusion protein were pulled down by Flag antibody and then detected by Western blot using HA antibody. The results showed that only p53b, but not p53a, could be co-immunoprecipitated by Flag-tagged sumo-1 (Fig. 2C).
Modification p53b-induced Cell Apoptosis was Enhanced by SUMO-1 Accumulation of p53b in Granulosa Cells

The expression and activity of p53 in granulosa cells was assessed by Western blot analysis. p53 protein levels were examined in mouse granulosa cells. p53b was overexpressed in granulosa cells, and the SUMO-1 modified versions of p53b were detected by Western blot analysis. The results showed that SUMO-1 modified p53b was detected in granulosa cells, and the SUMO-1 modified p53b was considered to be SUMOylated p53b. These results supported our hypothesis that mouse p53b could be SUMOylated in mouse granulosa cells. p53b is known to be involved in the regulation of cell apoptosis. Therefore, the activity of SUMOylation of p53b plays a crucial role in the function of p53b in mouse ovaries.

SUMO-1 Modification Enhanced the Protein Stability of p53b in a Dose-dependent Manner

Our results showed that the expression level of p53b increased in mouse granulosa cells. To further explore the patterns of SUMO-1 modification to enhance the stability of p53b, pre-GCs were co-transfected with HA-wild-type p53b or HA-p53b (K375R) plasmid and different amounts of Flag-sumo-1 plasmids. Total proteins were extracted and subjected to Western blot analysis with HA antibody (Fig. 3). As predicted, increasing the amount of Flag-sumo-1 plasmid for transfection resulted in a significant increase of both SUMOylated p53b and free p53b in a dose-dependent manner (Fig. 3A and B, compare lanes 3, 4, 5, and 6), but did not increase p53b (K375R) (Fig. 3C). These results demonstrated that SUMO-1 modification was responsible for increasing the stability of p53b in a dose-dependent manner, and further confirmed that Lys 375 was required for SUMOylation of p53b by SUMO-1.

SUMO-1 Modification was Required for the Nuclear Accumulation of p53b in Granulosa Cells

In order to study whether SUMO-1 modification of p53b at Lys375 is involved in the regulation of p53b's subcellular localization in granulosa cells, pre-GCs were transfected with HA-wild-type p53b or HA-p53b (K375R) plasmid and immunofluorescence cytochemistry was used to detect the subcellular localization of p53b protein by HA antibody. Wild type p53b proteins were accumulated only in the nucleus of pre-GCs, while mutant p53b (K375R) was localized in both nucleus and cytoplasm of pre-GCs (Fig. 4A). Meanwhile, the co-localization of SUMO-1 with p53b was observed in the nucleus of granulosa cells after co-transfection with sumo-1 plasmid and p53b plasmid. Mutant p53b (K375R) was still localized in both nucleus and cytoplasm of granulosa cells after co-transfection with sumo-1 plasmid and p53b (K375R) plasmid. Overall, the results indicated that SUMO-1 modification of p53b at Lys 375 was required for its nuclear accumulation in mouse granulosa cells.

p53b-induced Cell Apoptosis was Enhanced by SUMO-1 Modification

As p53 is a cellular gatekeeper [14,37], one of its roles is to survey cellular stress and induce apoptosis, if necessary. Therefore, we investigated the roles of mouse p53b in inducing apoptosis of pre-GCs. Cells were transfected with wild-type p53b or mutant p53b (K375R) for 24 h and then collected for apoptosis analysis by flow cytometer. The apoptosis rate was significantly increased by transfection with wild-type p53b compared with the control group and mutant p53b (K375R; Fig. 5A and 5B; P<0.05). The mutant p53b (K375R) transfected cells also showed significant increases in apoptosis compared with the control group (P<0.05), but were significantly lower in apoptosis compared with wild p53b transfected group (P<0.05). In addition, RT-PCR was used to detect the expression of a marker of apoptosis (Bax). Overexpression of either wild type p53b or mutant p53b (K375R) could significantly increase the expression of Bax mRNA, compared with control group. However, overexpression of wild type p53b could induce much higher expression level of Bax mRNA, compared with mutant p53b (Fig. 5C). These results were consistent with our other findings related to the apoptosis rate of granulosa cells. All these results implied that SUMO-1 modification of p53b enhanced the ability of p53b to induce apoptosis in pre-GCs. Mutating the SUMOylation site of p53b could significantly weaken the activity of p53b to induce apoptosis and apoptosis-related gene, Bax. On the other hand, in addition to inducing apoptosis, the cell death ratio was increased by mutation of p53b (K375R), but not by wild-type p53b (Fig. 5A).

Discussion

In normal cells, p53 is maintained at a low level, which is partly due to the short half-life of the protein [38]. However, in response to a variety of stress signals, p53 is stabilized, causing protein to accumulate and activating p53-dependent transcription. Related factors, including lower levels of the MDM2-mediated poly-ubiquitination of p53 and others, improved post-translational modifications [22–24].

Although human p53 had been reported to be modified by SUMO-1 [11,28,39], there are two kinds of p53 (p53a and p53b) in mouse; whether mouse p53 could be SUMOylated was unclear. In this study, overexpression of sumo-1 or ubc9 could increase the protein level of p53 in granulosa cells, and a specific migrating band was also observed by using HA antibody, implying that SUMOylation is involved in the stability of p53 protein by post-translational modification. Based on the prediction results of SUMOsp2.0.4 software, there is a conserved SUMOylated site at lys375 of p53b, but not in p53a. The results of IP confirmed that mouse p53b, but not p53a, could be SUMO-1 modified at lys375. Further experiments showed that lys375 mutation of p53b could result in its nucleus-cyttoplasm translocation and decrease its ability to induce apoptosis, confirming that p53b modified at lys375 by SUMO-1 plays crucial roles for p53 functions in granulosa cells.

The SUMO-1 modification increased the stabilization of mouse p53b in a dose-dependent manner (Fig. 3A); these results were similar to the results in U2OS cells, in which SUMO-1 modified form of p53 accumulated after UV irradiation [36]. However, several researchers have delineated a conserved pathway, in which SUMOylation and ubiquitination cooperate in protein degradation [40]. Topors is an ubiquitin and small ubiquitin-like modifier ubiquitin-protein isopeptidase ligase (SUMO E3) ligase [41]. Polo-like kinase 1 (Pik1) mediated phosphorylation of Topors inhibited Topors-mediated SUMOylation of p53, whereas p53 ubiquitination was enhanced, leading to p53 degradation [42], whether SUMOylation and ubiquitination of p53 cooperate in its degradation or the SUMOylation of p53 enhances the stabilization of p53 is still unclear. One research group proposed a hypothesis about an involvement of SUMOylation in p53 degradation [43], while there was some experimental evidences that SUMOylation may indeed facilitate p63 and p73 degradation [44,45]. Considering that in our results, the stabilization of p53b was increased by SUMOylation (perhaps because it prevented...
ubiquitination), SUMOylation of p53b may inhibit its degradation by competing for the same lysine residue that was required for p53 ubiquitination or by interfering with conjugation of ubiquitin molecules to neighboring sites [46]. However, further studies will be required to address this issue.

Another issue to be addressed is the role of the SUMO-1 modification pathway in the subcellular distribution of p53b. In normal cell circumstances, p53 protein is present in the nucleus, and p53 nuclear export is critical to determine their degradation; we can speculate that the distribution of p53 in the nucleus and cytoplasm is a key factor in determining its stability. Interestingly, it has been reported that p53-SUMO-1 fusion protein localize to PML bodies. While damages the use of the fusion proteins by mutating the C-terminal glycines in the SUMO-1 portion (ΔGG) to inhibit the formation of isopeptide bonds between SUMO-1 and target lysines, the localization of p53-SUMO-1ΔGG is predominantly at the nuclear envelope with some cytoplasmic staining [32]. Similarly, SUMOylation helped recruit Drosophila p53 to nuclear dot-like structures that could be marked by human PML and the Drosophila homologue of Daxx [34]. In our study, we also found that the localization of p53b was in the nucleus; after mutation, the nucleus localization was lost compared to wild p53b and part of the p53b was localized in the cytoplasm (Fig. 4 A and B). So our results directly demonstrated that SUMOylation was required for the nuclear localization of p53b, which provided a
novel platform for explaining why the SUMOylation of p53b increased its stabilization.

Research has firmly established that p53, is the cellular gatekeeper for growth, division, apoptosis, tumor suppression, and reproductive regulation [14,38,47]. Loss of the p53 gene in female mice leads to a significant decrease of fertility. The p53 gene product regulates maternal reproduction at the implantation stage of the embryo [48]. In addition, p53 is required for the induction of apoptosis [49]. Apoptosis of granulosa cells is an essential component of ovarian follicular atresia [50], and it has been reported that p53 protein is mainly expressed in the apoptotic granulosa cells of atretic follicles in the ovary [51,52].

Figure 4. SUMO-1 modification of p53b at Lys 375 was required for its nuclear accumulation in granulosa cells. (A) Pre-GCs were transfected with HA-tagged p53b or mutant p53b (K375R) plasmid, respectively. Then immunofluorescence cytochemistry was used to detect the subcellular localization of p53b or p53b (K375R) by HA antibody. The immunostaining signal of p53b were observed in nucleus of granulosa cells, but p53b (K375R) were seen in both nucleus and cytoplasm of granulosa cells (green). The nucleus was stained by PI (red). (B) Pre-GCs were co-transfected with HA-tagged p53b or mutant p53b (K375R) plasmid with Flag-tagged sumo-1 plasmid. Wild type p53b and mutant p53b (K375R) were detected by HA antibody with FITC-conjugated secondary antibody (green) and SUMO-1 was detected by SUMO-1 antibody with Cy3-conjugated secondary antibody (red), and the nucleus was stained by DAPI (blue). Co-localization of SUMO-1 and p53b in the nucleus were observed, but p53b (K375R) were still localized in both nucleus and cytoplasm of granulosa cells.

doi:10.1371/journal.pone.0063680.g004
Figure 5. SUMOylation of p53b induced apoptosis in granulosa cells.

(A) Representative flow cytometric analysis of apoptotic cells stained with Annexin V-FITC and PI after transfection with 2 μg wild type p53b, mutant p53b (K375R) plasmid, control plasmid or non-transfection control group for 24 h. In each panel, the lower right quadrant contains apoptotic cells (positive for Annexin V and negative for PI). (B) The apoptosis rate of granulosa cells. The value expressed by each bar represents the mean ± SD (n = 3). Different superscripts denote statistical difference at a P < 0.05. (C)
and p53 decreases the expression of the apoptosis-suppressing gene bel-2 while simultaneously increased the expression of Bax, a gene that encodes a dominant inhibitor of bel-2 protein [53,54]. Previous studies had shown that human p53 could be SUMO-1 modified, and when mutated the SUMOylation site lys386, the ability of p53 to induce apoptosis was weakened or even disappeared [33]. Mutation of both SUMOylation sites of Drosophila p53 dramatically reduced the transcriptional activity of p53 and its ability to induce apoptosis in transgenic flies [34]. In our study, SUMOylation of p53b enhanced the apoptosis in pre-GCs; mutating the SUMOylation site of p53b could significantly weaken the activity of p53b in inducing cells apoptosis (Fig. 5A and 5B). Actually, we also tested the effect of sumo-1 or sumo-1 co-transfection on apoptosis of granulosa cells, the results showed that sumo-1 transfection could also induce apoptosis of granulosa cells, but co-transfection with both p53 and sumo-1 has much more significant effect of inducing apoptosis of granulosa cells (data not shown). Meanwhile, overexpression of p53b significantly increased the expression of Bax (Fig. 5C). Interestingly, destruction of the SUMOylation site simultaneously decreased the expression of Bax (Fig. 5C). To some extent, p53b was regulated by SUMO-1 modification at the transcriptional level. However, further studies will be required to address whether SUMO-1 modification could enhance mouse p53b-dependent transactivation. Moreover, FSH is a potent survival factor of granulosa cells during follicular development. The future study about how FSH affects the SUMOylation of p53b-induced apoptosis during folliculogenesis will help us in better understanding of follicular development.

In conclusion, our data demonstrated that mouse p53b, but not p53a, can be SUMO-1 modified, and the SUMOylation site is lys375. The SUMOylation modification is clearly important for the functions of mouse p53b, regulating its stabilization, nucleus-cytoplasm translocation, and pro-apoptosis ability. These results provide important information about the roles and regulatory pathways of p53 in follicular granulosa cell apoptosis, follicular atresia, and ovarian cancer.

Acknowledgments

This work was conducted in the Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction, Education Ministry of China, College of Animal Science and Technology, Huazhong Agricultural University. We are also grateful to Yao Hang (State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University) for providing technical assistance for confocal microscopy.

Author Contributions

Conceived and designed the experiments: XML LJH. Performed the experiments: XML FFY YFY RZ. Analyzed the data: XML LJH. Wrote the paper: XML LJH.

References

1. Hughes FM, Jr., Goroopse WC (1991) Biochemical identification of apoptosis (programmed cell death) in granulosa cells: a potential mechanism underlying follicular atresia. Endocrinology 129: 2415–2422.
2. Gougeon A (1996) Regulation of ovarian follicular development in primates: facts and hypotheses. Endo Rev 17: 121–135.
3. Jiang JY, Cheung C, Wang Y, Tsang BK (2003) Regulation of cell death and cell survival gene expression during ovarian follicular development and atresia. Front Biosci 8: 222–237.
4. Kazma A, Higashi JF (1997) Regulation of ovarian follicle atresia. Annu Rev Physiol 59: 349–363.
5. Perez GI, Robles K, Knudson CM, Flaws JA, Korumyey SJ, et al. (1999) Prolongation of ovarian lifespan into advanced chronological age by Bax deficiency. Nature genetics 21: 200–203.
6. Talby JI, Kowalski KI, Johnson AL, Hsieh AJ (1991) Involvement of apoptosis in ovarian follicular atresia and postovulatory regression. Endocrinology 129: 2799–2801.
7. Harshfield AN (1991) Development of follicles in the mammalian ovary. Int Rev Cytol 124: 45–101.
8. Boone DL, Carnegie JA, Rippstein PU, Tsang BK (1997) Induction of apoptosis in equine chorionic gonadotropin (eCG)-primed rat ovaries by anti-eCG antibody. Biol Reprod 57: 420–427.
9. Crook T, Marston NJ, Sara EA, Vossen KH (1994) Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79: 817–827.
10. Matsuda-Minehata F, Inoue N, Goto Y, Manabe N (2006) The pathways of p53 in follicular granulosa cell apoptosis, follicular atresia, and ovarian cancer.
11. MATSUDA-MINEHATA F, Maeda A, Cheng Y, Sai T, Gonda H, et al. (2008) Regulation of granulosa cell apoptosis by death ligand–receptor signaling. Front Biosci 8: d222–d237.
12. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909–923.
13. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes & development 10: 1654.
14. Levine AJ (1997) p53, the cellular gatekeeper review for growth and division. Animal Science Journal 79: 1–10.
15. Mu¨ller S, Hoege C, Pyrowolakis G, Jentsch S (2001) SUMO, ubiquitin's mysterious cousin. Nature reviews Molecular cell biology 2: 202.
16. Kim JM, Yoon YD, Tsang BK (1999) Involvement of the Fas/Fas ligand system in p53-mediated granulosa cell apoptosis during follicular development and atresia. Endocrinology 140: 2307–2317.
17. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes & development 10: 1654.
18. Ruaro EM, Collavin L, Del Sal G, Haffner R, Oren M, et al. (1997) A proline-rich motif in p53 is required for transcriptional-independent growth arrest as induced by G2I. Proceedings of the National Academy of Sciences 94: 4675.
19. Asselin E, Xiao CW, Wang YF, Tsang BK (2000) Mammalian follicular development and atresia: role of apoptosis. Biol Signals Recept 9: 87–95.
20. Melchior F (2000) SUMO-nonclassical ubiquitin. Annual review of cell and developmental biology 16: 591–626.
21. cholmery FM, NOD, YITO K, MANABE N (2006) The pathways of p53 in follicular granulosa cell apoptosis, follicular atresia, and ovarian cancer.
22. Mello PB, Koshland D (1995) Evidence that the MIF2 gene of Saccharomyces cerevisiae encodes a centromere protein with homology to the mammalian centromere protein CENP-C. Molecular biology of the cell 6: 793.
23. Muller S, Hoege C, Pyrowolakis G, Jenstch S (2001) SUMO, ubiquitin's mysterious cousin. Nature reviews Molecular cell biology 2: 202.
24. Gostissa M, Hengstler A, Fogal V, Sandy P, Schwarz SE, et al. (1999) Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. The EMBO journal 18: 6462–6471.
25. Rodrigo MS, Desterro JMP, Lain S, Middeley CA, Lane DP, et al. (1999) SUMO-1 modification activates the transcriptional response of p53. Science's STKE 10: 6455.
31. Schmidt D, Muller S (2002) Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci U S A 99: 2072–2077.
32. Carter S, Vousden KH (2008) p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 7: 2519–2528.
33. Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y, et al. (2000) c-Jun and p53 activity is modulated by SUMO-1 modification. Journal of Biological Chemistry 275: 13321–13329.
34. Mauri F, McNamee LM, Lunardi A, Chiaretti F, Del Sal G, et al. (2008) Modification of Drosophila p53 by SUMO modulates its transactivation and pro-apoptotic functions. Journal of Biological Chemistry 283: 20848–20856.
35. Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, et al. (1999) Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J 18: 6462–6471.
36. Rodríguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, et al. (1999) SUMO-1 modification activates the transcriptional response of p33. EMBO J 18: 6455–6461.
37. Kindey P, Vogelstein B (1997) Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386: 761–763.
38. Hoshid J, Hsuain SP, Harris CC (2004) p53: 25 years after its discovery. Trends Pharmacol Sci 25: 177–181.
39. Hay RT (2005) SUMO: a history of modification. Mol Cell 18: 1–12.
40. Perry JJ, Tainer JA, Boddy MN (2000) A SIM-ultraneous role for SUMO and ubiquitin. Trends Biochem Sci 25: 201–208.
41. Weger S, Hammer E, Heilbronn R (2005) Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS letters 579: 5007–5012.
42. Yang X, Li H, Zhou Z, Wang WH, Deng A, et al. (2009) Pkl-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem 284: 18588–18592.
43. Stehncier P, Muller S (2009) Regulation of p53 family members by the ubiquitin-like SUMO system. DNA repair 8: 491–498.
44. Balkers J, Camacho-Carvalho M, Nowak M, Kramer G, Danger B, et al. (2005) Report Destabilization of Dnp63a by Nedd4-Mediated Ubiquitination and Ubc9-Mediated Sumoylation, and Its Implications on Dorsoventral Patterning of the Zebrafish Embryo. Cell Cycle 4: 790–800.
45. Ghiomi P, D’Alessandra V, Mauzaoro G, Jaffray E, Hay RT, et al. (2005) The protein stability and transcriptional activity of p63alpha are regulated by SUMO-1 conjugation. Cell Cycle 4: 183–190.
46. Ulrich HD (2005) Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. Trends in cell biology 15: 525–532.
47. Hu W (2009) The role of p53 gene family in reproduction. Cold Spring Harbor perspectives in biology 1.
48. Hu W, Feng Z, Teresky AK, Levine AJ (2007) p53 regulates maternal reproduction through LIF. Nature 450: 721–724.
49. Meekranz W, Schlegel R (1993) Apoptosis and the cell cycle. Journal of cellular biochemistry 58: 160–174.
50. Hussein MR (2005) Apoptosis in the ovary: molecular mechanisms. Human reproduction update 11: 162–178.
51. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin H, et al. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799.
52. Tilly J, Tilly K, Kenton M, Johnson A (1995) Expression of members of the bcl-2 gene family in the immature rat ovary: equine chorionic gonadotropin-mediated inhibition of granulosa cell apoptosis is associated with decreased bax and constitutive bcl-2 and bcl-xl messenger ribonucleic acid levels. Endocrinology 136: 232–241.
53. Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews Cancer 2: 454–465.
54. Mihara M, Ester S, Zsaka A, Petrenko O, Chittenden T, et al. (2003) p53 has a direct apoptogenic role at the mitochondria. Molecular cell 11: 577–590.